Compugen Ltd
CGEN
Market Cap$155.23M
Close$
$2.54
46.1% upside
Current Fair Value
46.1% upsideUndervalued by 46.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $155.23 Million |
|---|---|
| Enterprise Value | $153.05 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.16 |
| Beta | 2.55 |
| Outstanding Shares | 92,308,225 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -10.83 |
|---|---|
| PEG | 915.38 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 5.55 |
| Enterprise Value to EBIT | -10.35 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.22 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Compugen Ltd
CEO: Anat Cohen-Dayag Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immu...